

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/644,594	08/19/2003	Tony N. Frudakis	DNA1170-2	6207
DLA PIPER U 4365 EXECUT		7	EXAMINER AGRAWAL, RITESH	
SUITE 1100 SAN DIEGO, CA 92121-2133			ART UNIT	PAPER NUMBER
,			1631	
			MAIL DATE	DELIVERY MODE
			06/06/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/644,594	FRUDAKIS ET A	AL.
Office Action Summary	Examiner	Art Unit	
	Ritesh Agrawal	1631	
The MAILING DATE of this communication app Period for Reply	ears on the cover sheet w	with the correspondence a	ddress
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period was precised to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 36(a). In no event, however, may a vill apply and will expire SIX (6) MC cause the application to become	ICATION.  a reply be timely filed  ONTHS from the mailing date of this ABANDONED (35 U.S.C. § 133).	,
Status			
1) Responsive to communication(s) filed on 26 M	<u> </u>		
·	action is non-final.		
3) Since this application is in condition for allowar		•	ne merits is
closed in accordance with the practice under E	x parte Quayle, 1955 C.	D. 11, 453 O.G. 213.	
Disposition of Claims			
4) ⊠ Claim(s) <u>1,3,5,6,8,9,24,29-32,37,39-45 and 47-4a</u> ) Of the above claim(s) is/are withdray 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1,3,5,6,8,9,24,29-32,37,39-45 and 47-48-48</u>	vn from consideration.		rement.
Application Papers		·	
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) access applicant may not request that any objection to the Replacement drawing sheet(s) including the correction of the oath or declaration is objected to by the Examine 11).	epted or b) objected to drawing(s) be held in abeya ion is required if the drawin	ance. See 37 CFR 1.85(a). g(s) is objected to. See 37 C	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in a ity documents have been (PCT Rule 17.2(a)).	Application No n received in this Nationa	l Stage
			•
	•		•
Attachment(s)			
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-948)</li> <li>Information Disclosure Statement(s) (PTO/SB/08)</li></ol>	Paper No	Summary (PTO-413) (s)/Mail Date Informal Patent Application	

## **DETAILED ACTION**

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

Claims 1, 5, and 31 recite several different possible combinations of nucleic acid sequences.

Applicants are required to select a single combination of nucleic acid sequences (e.g. 1-10, 1-50, 20-40, 1-331, etc.) to which the claims will be restricted.

The inventions are distinct, each from the other because of the following reasons:

The Inventions comprising the different sets of nucleic acid sequences are directed to related products. The related inventions are distinct if the (1) the inventions as claimed are either not capable of use together or can have a materially different design, mode of operation, function, or effect; (2) the inventions do not overlap in scope, i.e., are mutually exclusive; and (3) the inventions as claimed are not obvious variants. See MPEP § 806.05(j). In the instant case, the inventions as claimed the inventions are directed to different nucleic acid sequences, each having a different design where there is no indication that the nucleic acid sequences represent obvious variants. As each individual nucleic acid sequence requires a separate search, a search of all the nucleic acids sequences (and possible combinations thereof) represents a search burden. Furthermore, the inventions as claimed do not encompass overlapping subject matter and there is nothing of record to show them to be obvious variants.

Application/Control Number: 10/644,594

Art Unit: 1631

Because these inventions are independent or distinct for the reasons given above and there would be a serious burden on the examiner if restriction is not required because the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 10/644,594 Page 4

Art Unit: 1631

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ritesh Agrawal whose telephone number is (571) 272-2906. The examiner can normally be reached on 8:30 AM - 5:00 PM M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ram Shukla can be reached on 571-272-0735. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Ritesh Agrawal

JOHN S. BRUSCA, PH.D PRIMARY EXAMINER

B. Bruser Jun 2007